source
- Precision strategies help de-risk rare disease therapy launchesCommercializing a rare disease therapy presents a high‑risk, high‑reward scenario for biotech firms. Small patient populations, stringent regulatory requirements, and the need to sustain value beyo…
- Biopharma manufacturers turn to flexible, modular facilities to meet diverse therapy demandsBiopharma development is increasingly focused on specialized and personalized treatments such as cell and gene therapies, antibody-drug conjugates and monoclonal antibodies. At the same time, the m…